Formulary Watch |

All News - Page 3

Ventegra Launches Point-of-Sale Rebate Program
Ventegra Launches Point-of-Sale Rebate Program
Ventegra Launches Point-of-Sale Rebate Program
April 10, 2024
Ventegra, which provides drug benefit solutions, is also converting to a nonprofit status, which will be completed June 30, 2024.
appledesign-stock.adobe.com
Drugs to Watch: Lung Cancer
Drugs to Watch: Lung Cancer
April 10, 2024
The FDA is currently reviewing tarlatamab for small-cell lung cancer with a review date in June and datopotamab deruxtecan for non-small cell lung cancer with a review date in the fourth quarter.
Алексей Закиров
Humira Biosimilars Have a Slow Uptake, Finds Samsung Bioepis Report
Humira Biosimilars Have a Slow Uptake, Finds Samsung Bioepis Report
April 8, 2024
Caps on Medicare Part D cost sharing as a result of the Inflation Reduction Act, could reduce members’ financial incentive for switching to a biosimilar, suggests the newest Samsung Bioepis Quarterly Biosimilar Market Report.
Tuft’s Joshua Cohen Talks about Quality-Adjusted Life-Years
Tuft’s Joshua Cohen Talks about Quality-Adjusted Life-Years
Tuft’s Joshua Cohen Talks about Quality-Adjusted Life-Years
April 5, 2024
The quality-adjusted life-years tool has been misunderstood, Dr. Joshua Cohen says. QALYs are a measure of the value that comes from restoring a person to health, not about discrimination.
Amylyx Pulls ALS Treatment Off Market With a Few Thousand Still on Treatment as of Late '23
Amylyx Pulls ALS Treatment Off Market With a Few Thousand Still on Treatment as of Late '23
Amylyx Pulls ALS Treatment Off Market With a Few Thousand Still on Treatment as of Late '23
April 5, 2024
Approved in late September 2022, Relyvrio will no longer be available for new amyotrophic lateral sclerosis (ALS) patients.
FDA Accepts Supplemental BLA for Bimzelx in Hidradenitis Suppurativa
FDA Accepts Supplemental BLA for Bimzelx in Hidradenitis Suppurativa
FDA Accepts Supplemental BLA for Bimzelx in Hidradenitis Suppurativa
April 4, 2024
The FDA is also considering a separate BLA for a 2 mL syringe. Bimzelx is already available to treat plaque psoriasis as a 1 ml syringe; a dose is two subcutaneous injections with a cost of $7,200 per syringe.
thanksforbuying-stock-adobe.com
IRA is Expected to Cut Out-of-Pocket Costs by 28% for Women in Medicare
IRA is Expected to Cut Out-of-Pocket Costs by 28% for Women in Medicare
April 2, 2024
In 2025, the out-of-pocket cap and other Part D related provisions in the Inflation Reduction Act are projected to save women in Medicare an average of 28% in out-of-pocket costs, according to a new analysis from the Office of the Assistant Secretary for Planning and Evaluation.
ICER to Shine a Light on Clinical Trial Diversity
ICER to Shine a Light on Clinical Trial Diversity
ICER to Shine a Light on Clinical Trial Diversity
March 28, 2024
Foluso Agboola discusses the framework that the Institute for Clinical and Economic Review has developed for assessing whether clinical trial populations represent the real-world patient population.
tashatuvango-stock.adobe.com
FDA Approves Vafseo for Anemia in Kidney Disease
FDA Approves Vafseo for Anemia in Kidney Disease
March 28, 2024
Vafseo, an oral therapy to treat patients with anemia due to chronic kidney, will be available in January 2025. About 40% of patients who could be treated with Vafseo have coverage through Medicare Advantage plans.
OpturaDesign-stock.abode.com
Medicare’s Spending on Ozempic and Other GLP-1s Rises Steeply
Medicare’s Spending on Ozempic and Other GLP-1s Rises Steeply
March 27, 2024
Ozempic and Rybelsus could become a target for Medicare price negotiation because of high spending and additional approved uses of the GLP-1 therapies.
 FDA Approves Merck’s Drug for Pulmonary Arterial Hypertension
 FDA Approves Merck’s Drug for Pulmonary Arterial Hypertension
FDA Approves Merck’s Drug for Pulmonary Arterial Hypertension
March 26, 2024
Sotatercept — now with the brand name Winrevair — will be available through specialty pharmacies by the end of April. The price of Winrevair is $14,000 per vial.
 adrian_ilie825-stock.adobe.com
CMS Estimates Savings for Patients from Medicare Inflation Rebates
CMS Estimates Savings for Patients from Medicare Inflation Rebates
March 26, 2024
Medicare Part B beneficiaries may save between $1 and $3,575 per average dose for the 41 drugs whose prices have risen higher than inflation.
Medicaid, Medicare Part D to Provide Coverage of Wegovy, But Not for Weight Loss
Medicaid, Medicare Part D to Provide Coverage of Wegovy, But Not for Weight Loss
Medicaid, Medicare Part D to Provide Coverage of Wegovy, But Not for Weight Loss
March 22, 2024
Medicare and Medicaid will cover Wegovy for its recently approved indication to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and obesity.
GSK Caps Respiratory Medications at $35 a Month
GSK Caps Respiratory Medications at $35 a Month
GSK Caps Respiratory Medications at $35 a Month
March 21, 2024
This follows AstraZeneca’s and Boehringer Ingelheim’s announcements to also cap their asthma chronic obstructive pulmonary disease drugs at $35.
FDA Approves Drug that Treats Hypertension in a New Way
FDA Approves Drug that Treats Hypertension in a New Way
FDA Approves Drug that Treats Hypertension in a New Way
March 21, 2024
Tryvio, an oral drug for those with uncontrolled hypertension, will be available in the second half of 2024. The list price has not yet to be determined.
ktsdesign-stock.adobe.com
New Gene Therapy for Rare MDL to Cost $4.25 Million
New Gene Therapy for Rare MDL to Cost $4.25 Million
March 20, 2024
Lenmeldy is the first approved gene therapy to treat children with juvenile metachromatic leukodystrophy, a life-threatening inherited disease of the body’s metabolic system.
Celltrion Launches Zymfentra, a Subcutaneous Form of Infliximab
Celltrion Launches Zymfentra, a Subcutaneous Form of Infliximab
Celltrion Launches Zymfentra, a Subcutaneous Form of Infliximab
March 20, 2024
Zymfentra, with a price of $6,181.08 for two shots over four weeks, is approved as maintenance therapy for adults with ulcerative colitis and Crohn’s disease.
© 2024 MJH Life Sciences

All rights reserved.